Search Results

bevacizumab to cisplatin/pemetrexed (with maintenance bevacizumab) versus cisplatin/pemetrexed alone for patients with unresectable PM and performance status (PS) 0–2 who did not have any substantial cardiovascular comorbidity. 46 OS was longer in the

erlotinib plus bevacizumab. Response to Gemcitabine-Based Treatments A total of 88% of patients (50/57) who received a gemcitabine-based regimen were evaluable for response ( Table 2 ), including 37 of 41 patients who received gemcitabine

trial. 35 The results of AVAglio and RTOG 0825, 2 studies examining the addition of bevacizumab to radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, were recently presented. 39 , 40 Neither study showed an OS advantage with

German GeparSixto study, 1 the inclusion of carboplatin improved the pathologic complete response (pCR) rate compared with paclitaxel, nonpegylated liposomal doxorubicin, and bevacizumab used alone among those patients with triple-negative breast cancer

to determine benefit from adjuvant chemotherapy; there is a similar lack of data for ‘high-risk’ stage II disease and benefit from adjuvant chemotherapy.” 3 Finally, adding the biologic bevacizumab or cetuximab did not appear to offer an advantage

benefit of adding targeted biologic agents, such as bevacizumab and cetuximab, is being tested. Initial phase I/II trials of bevacizumab plus preoperative 5-FU or capecitabine-based chemoradiation revealed pCR rates of 18% to 24%. 17 , 18 However, more

, interferon alfa, or both for advanced renal-cell carcinoma . N Engl J Med 2007 ; 356 : 2271 – 2281 . 40 Yang JC Haworth L Sherry RM . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal

responsiveness to the anti–epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab. 9 , 10 Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), has also been shown to improve survival in the first

therapies, including immunotherapies (interleukin-2 and nivolumab) and molecularly targeted therapies, which comprise angiogenesis inhibitors (bevacizumab, sunitinib, sorafenib, pazopanib, axitinib, and, with a characteristic target spectrum, the recently

empiric, usually a platinum-based doublet. However in 2006, the FDA approved use of the anti-vascular endothelial growth factor monoclonal antibody, bevacizumab, with paclitaxel and carboplatin (PCB). This approval was based on the results of the ECOG